Literature DB >> 33719028

Update on molecular biomarkers for diagnosis and prediction of prognosis and treatment responses in gastric cancer.

Masahiro Sasahara1, Mitsuro Kanda2, Yasuhiro Kodera1.   

Abstract

Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide, and its high mortality rate is a serious problem in many regions. To improve prognosis, it is necessary to identify novel biomarkers for the early detection of GC, along with its prognosis, risk of metastatic recurrence, and predicted response to chemotherapy, and to develop individualized treatment strategies. Advances in microarray and sequencing techniques have led to the elucidation of cancer-related gene mutations and aberrant expression levels, which have deepened our knowledge of GC. Further searches for sensitive biomarkers are needed to improve the management of patients with GC. In this review article, we update the current knowledge of GC biomarkers, examine recently published literature, and introduce some representative molecules.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33719028     DOI: 10.14670/HH-18-326

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  126 in total

1.  CD40 DNA hypermethylation in primary gastric tumors; as a novel diagnostic biomarker.

Authors:  Mohammad Amini; Khodayar Ghorban; Ahad Mokhtarzadeh; Maryam Dadmanesh; Behzad Baradaran
Journal:  Life Sci       Date:  2020-05-11       Impact factor: 5.037

2.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

3.  Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.

Authors:  Jaffer A Ajani; Jeannelyn S Estrella; Qiongrong Chen; Arlene M Correa; Lang Ma; Ailing W Scott; Jiankang Jin; Bin Liu; Min Xie; Kazuki Sudo; Hironori Shiozaki; Brian Badgwell; Brian Weston; Jeffrey H Lee; Manoop S Bhutani; Hisashi Onodera; Koyu Suzuki; Akihiro Suzuki; Sheng Ding; Wayne L Hofstetter; Randy L Johnson; Robert S Bresalier; Shumei Song
Journal:  Br J Cancer       Date:  2017-11-14       Impact factor: 7.640

4.  Cell-free miR-17-5p as a diagnostic biomarker for gastric cancer inhibits dendritic cell maturation.

Authors:  Zi-Jin Cui; Xiao-Li Xie; Wei Qi; Yi-Chao Yang; Yun Bai; Jing Han; Qian Ding; Hui-Qing Jiang
Journal:  Onco Targets Ther       Date:  2019-04-09       Impact factor: 4.147

5.  Prognostic role of ARID1A negative expression in gastric cancer.

Authors:  Mai Ashizawa; Motonobu Saito; Aung Kyi Thar Min; Daisuke Ujiie; Katsuharu Saito; Takahiro Sato; Tomohiro Kikuchi; Hirokazu Okayama; Shotaro Fujita; Hisahito Endo; Wataru Sakamoto; Tomoyuki Momma; Shinji Ohki; Akiteru Goto; Koji Kono
Journal:  Sci Rep       Date:  2019-05-01       Impact factor: 4.379

Review 6.  CHFR Promoter Hypermethylation Is Associated with Gastric Cancer and Plays a Protective Role in Gastric Cancer Process.

Authors:  Dongjun Dai; Bingluo Zhou; Wenxia Xu; Hongchuan Jin; Xian Wang
Journal:  J Cancer       Date:  2019-01-29       Impact factor: 4.207

Review 7.  Gastric biomarkers: a global review.

Authors:  Nick Baniak; Jenna-Lynn Senger; Shahid Ahmed; S C Kanthan; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2016-08-11       Impact factor: 2.754

8.  Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer.

Authors:  Alexander S Brodsky; Jinjun Xiong; Dongfang Yang; Christoph Schorl; Mary Anne Fenton; Theresa A Graves; William M Sikov; Murray B Resnick; Yihong Wang
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

9.  Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway.

Authors:  Chen Cai; Wei Dang; Shilei Liu; Ling Huang; Yang Li; Guoqiang Li; Siyuan Yan; Chengkai Jiang; Xiaoling Song; Yunping Hu; Jun Gu
Journal:  Cancer Sci       Date:  2020-01-24       Impact factor: 6.716

10.  SIK2 represses AKT/GSK3β/β-catenin signaling and suppresses gastric cancer by inhibiting autophagic degradation of protein phosphatases.

Authors:  Xiao-Man Dai; Yan-Hui Zhang; Xiao-Han Lin; Xiao-Xing Huang; Yi Zhang; Chao-Rong Xue; Wan-Nan Chen; Jian-Xin Ye; Xin-Jian Lin; Xu Lin
Journal:  Mol Oncol       Date:  2020-11-20       Impact factor: 6.603

View more
  2 in total

1.  Clinical outcomes and potential therapies prediction of subgroups based on a ferroptosis-related long non-coding RNA signature for gastric cancer.

Authors:  Haigang Geng; Ruolan Qian; Linmeng Zhang; Chen Yang; Xiang Xia; Cun Wang; Gang Zhao; Zizhen Zhang; Chunchao Zhu
Journal:  Aging (Albany NY)       Date:  2022-08-14       Impact factor: 5.955

Review 2.  The emerging role of miR-10 family in gastric cancer.

Authors:  Fang Liu; Yanfen Shi; Zuolong Liu; Ziyi Li; Wei Xu
Journal:  Cell Cycle       Date:  2021-07-07       Impact factor: 5.173

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.